×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Should You Pick Bristol Myers Squibb Stock At $45?
Forbes
Bristol Myers Squibb (NYSE: BMY) recently reported its Q1 results, with revenues and earnings above the street estimates.
3 days ago
Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
Yahoo Finance
Keep your goals in check when considering an extreme contrarian trade with Bristol Myers Squibb stock.
1 day ago
If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today
The Motley Fool
It's a reasonable question: If you'd invested $1,000 in pharmaceutical specialist Bristol Myers Squibb (BMY 0.66%) five years ago in 2019,...
1 day ago
Bristol-Myers Squibb Stock: A Lost Decade? (NYSE:BMY)
Seeking Alpha
Bristol-Myers Squibb's stock soars in 2022 on pipeline success, but concerns over patent gap and debt overshadow growth prospects.
1 day ago
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
GlobeNewswire
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases...
3 days ago
Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
The Motley Fool
Keep your goals in check when considering an extreme contrarian trade with Bristol Myers Squibb stock. Some investors view growth or...
1 day ago
If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today
Yahoo Finance
It's a reasonable question: If you'd invested $1,000 in pharmaceutical specialist Bristol Myers Squibb (NYSE: BMY) five years ago in 2019,...
1 day ago
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Yahoo Finance
Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.
1 day ago
Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
CNBC
Bristol Myers Squibb reported first-quarter revenue that topped expectations as sales of its popular blood cancer treatment Revlimid and...
1 week ago
Bristol Myers Squibb CEO Christopher Boerner outlines plans
STAT
Christopher Boerner, 53, took over as the chief executive officer of Bristol Myers Squibb last November, and immediately made a big move: a...
1 week ago